| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 0 | |||
| Research and development | 32,321,000 | |||
| General and administrative | 7,350,000 | |||
| Change in fair value of contingent consideration | 109,000 | |||
| Total operating expenses | 39,780,000 | |||
| Operating loss | -39,780,000 | |||
| Interest income | 1,708,000 | |||
| Interest expense | 10,000 | |||
| Other expense, net | -117,000 | |||
| Total other income, net | 1,581,000 | |||
| Loss before income taxes | -38,199,000 | |||
| Income tax provision | 63,000 | |||
| Net loss | -38,262,000 | |||
| Foreign currency translation adjustment | -306,000 | |||
| Unrealized loss on marketable securities, net of tax | -86,000 | |||
| Total other comprehensive (loss) income | -392,000 | |||
| Comprehensive loss | -38,654,000 | |||
| Basic EPS | -6.77 | |||
| Diluted EPS | -6.77 | |||
| Basic Average Shares | 5,655,716 | |||
| Diluted Average Shares | 5,655,716 | |||
Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)